DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease

Clinical and Experimental Rheumatology

Volumn 21, Issue 5 SUPPL. 31, 2003, Pages

  Aletaha, Daniel ^a   Smolen, Josef S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Early DMARD therapy; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; GLUCOCORTICOID; GOLD DERIVATIVE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

CLINICAL OBSERVATION; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; PATIENT CARE; PATIENT REFERRAL; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CONTROLLED CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROGNOSIS; RANGE OF MOTION, ARTICULAR; RECOVERY OF FUNCTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0142061680     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. COHEN S, HURD E, CUSH J et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24.
2. MAINI R, st CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
3. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
4. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
5. SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353: 259-66.
6. EMERY P, SALMON M: Early rheumatoid arthritis: Time to aim for remission? Ann Rheum Dis 1995; 54: 944-7.
7. NELL VPK, MACHOLD KP, EBERL G, STAMM T, UFFMANN M, SMOLEN IS: The benefit of very early referral and therapy with disease modifying antirheumatic drugs in patients with early rheumatoid arthritis. Arthritis Rheum 2002; 46 (Suppl. 9): S334.
8. LARD LR, VISSER H, SPEYER I et al.: Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446-51.
9. van der HA, JACOBS JW, BIJLSMA JW et al.: The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Anti Intern Med 1996; 124: 699-707.
10. ANDERSON JJ, WELLS G, VERHOEVEN AC, FELSON DT: Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration. Arthritis Rheum 2000; 43: 22-9.
11. LANDEWE RB, BOERS M, VERHOEVEN AC et al.: COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347-56.
12. BUKHARI MA, WILES NJ, LUNT M et al.: Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003; 48: 46-53.
13. BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
14. MÖTTÖNEN T, HANNONEN P, LEIRISALO-REPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FINRACo trial group. Lancet 1999; 353: 1568-73.
15. DOUGADOS M, COMBE B, CANTAGREL A et al.: Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58: 220-5.
16. FURST DE, LINDSLEY H, BAETHGE B et al.: Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 1999; 42: 357-65.
17. HAAGSMA CJ, van RIEL PL, de JONG AJ, van de PUTTE LB: Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36: 1082-8.
18. LANDEWE RB, GOEI THE HS, van RIJTHOVEN AW, BREEDVELD FC, DIJKMANS BA: A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994; 37: 637-43.
19. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med 1995; 98: 156-68.
20. PROUDMAN SM, CONAGHAN PG, RICHARDSON C et al.: Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43: 1809-19.
21. van JAARSVELD CH, JACOBS JW, van der VEEN MJ et al.: Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. Ann Rheum Dis 2000; 59: 468-77.
22. WOOLF AD, HALL ND, GOULDING NJ et al.: Predictors of the long-term outcome of early synovitis: A 5-year follow-up study. Br J Rheumatol 1991; 30: 251-4.
23. ALETAHA D, SMOLEN JS: Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002; 29: 1631-8.
24. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
25. WEINBLATT ME: Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol 1995; 34 (Suppl. 2): 43-8.
26. WEINBLATT ME, REDA D, HENDERSON W et al.: Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol 1999; 26: 2123-30.
27. ALETAHA D, SMOLEN JS: The rheumatoid arthritis patient in the clinic: Comparing more than 1300 consecutive DMARD courses. Rheumatology 2002; 41: 1367-74.
28. DEVLIN J, GOUGH A, HUISSOON A et al.: The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 1997; 24: 9-13.
29. van LEEUWEN MA, van RIJSWIJK MH, van der HEIJDE DM et al.: The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993; 32 (Suppl. 3): 9-13.
30. WOLFE F: Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997; 24: 1477-85.
31. ALETAHA D, EBERL G, NELL VP, MACHOLD KP, SMOLEN JS. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis 2002; 61: 630-4.
32. MACHOLD KP, STAMM TA, EBERL GJ, et al.: Very recent onset arthritis - Clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002; 29: 2278-87.
33. GREEN M, MARZO-ORTEGA H, McGONAGLE D et al.: Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 1999; 42: 2184-8.
34. DROSSAERS-BAKKER KW, ZWINDERMAN AH, VLIELAND TP et al.: Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 2002; 47: 383-90.
35. de la MATA J, BLANCO FJ, GOMEZ-REINO JJ: Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. Ann Rheum Dis 1995; 54: 881-5.
36. WIJNANDS MJ, van't HOF MA, van LEEUWEN MA, van RIJSWIJK MH, van de PUTTE LB, van RIEL PL: Long-term second-line treatment: A prospective drug survival study. Br J Rheumatol 1992; 31: 253-8.